Antipsychotic medication influences the discriminative value of acylethanolamides as biomarkers of substance use disorder

Plasma acylethanolamides (NAEs), including the endocannabinoid anandamide (AEA), have been proposed as circulating biomarkers of substance use disorders. However, the concentration of these lipid transmitters might be influenced by the use of drugs prescribed for either the treatment of addiction or...

Descripción completa

Detalles Bibliográficos
Autores: Herrera-Imbroda, Jesús, Flores-López, María, Requena-Ocaña, Nerea, Araos, Pedro, Ropero, Jessica, García Marchena, Nuria, Bordallo, Antonio, Suarez, Juan, Pavón-Morón, Francisco Javier, Serrano, Antonia, Mayoral, Fermín, Rodríguez De Fonseca, Fernando Antonio
Tipo de recurso: artículo
Fecha de publicación:2023
País:España
Institución:Universidad Complutense de Madrid (UCM)
Repositorio:Docta Complutense
Idioma:inglés
OAI Identifier:oai:docta.ucm.es:20.500.14352/104152
Acceso en línea:https://hdl.handle.net/20.500.14352/104152
Access Level:acceso abierto
Palabra clave:616.89
Substance use disorders
Biomarkers
Endocannabinoids
Acylethanolamides
Neuroleptics
Psychiatric co-morbidity
Psicofarmacología
Toxicología (Medicina)
32 Ciencias Médicas
id ES_23b353bacb4e648f94bbb05e27de7bd8
oai_identifier_str oai:docta.ucm.es:20.500.14352/104152
network_acronym_str ES
network_name_str España
repository_id_str
spelling Antipsychotic medication influences the discriminative value of acylethanolamides as biomarkers of substance use disorderHerrera-Imbroda, JesúsFlores-López, MaríaRequena-Ocaña, NereaAraos, PedroRopero, JessicaGarcía Marchena, NuriaBordallo, AntonioSuarez, JuanPavón-Morón, Francisco JavierSerrano, AntoniaMayoral, FermínRodríguez De Fonseca, Fernando Antonio616.89Substance use disordersBiomarkersEndocannabinoidsAcylethanolamidesNeurolepticsPsychiatric co-morbidityPsicofarmacologíaToxicología (Medicina)32 Ciencias MédicasPlasma acylethanolamides (NAEs), including the endocannabinoid anandamide (AEA), have been proposed as circulating biomarkers of substance use disorders. However, the concentration of these lipid transmitters might be influenced by the use of drugs prescribed for either the treatment of addiction or the associated psychiatric co-morbidities such as psychosis. As an example, neuroleptics, used for attenuation of psychotic symptoms and sedation, might theoretically interfere with the monoamine-mediated production of NAEs, obstructing the interpretation of plasma NAEsasclinical biomarkers. To solve the lack of information on the impact of neuroleptics on the concentration of NAEs, we evaluated the concentrations of NAEs in a control group and compared them to those present in (a) substance use disorders (SUD) patients that are not prescribed with neuroleptics, and (b) SUD patients (both alcohol use disorder and cocaine use disorder patients) using neuroleptics. The results demonstrate that SUD patients exhibited greater concentrations of NAEsthan the control population, affecting all species with the exception of stearoylethanolamide (SEA) and palmitoleoylethanolamide (POEA). Neuroleptic treatment enhanced the concentrations of NAEs, especially those of AEA, linoleoylethanolamide (LEA), and oleoylethanolamide (OEA). This effect of neuroleptic treatment was observed independently of the drug addiction that motivated the demand for treatment (either alcohol or cocaine). This study remarks the need to control the current use of psychotropic medication as a potential confounding variable when considering the use of NAEsasbiomarkers in SUD.MDPIUniversidad Complutense de Madrid20232023-05-2720232023-05-27journal articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/20.500.14352/104152reponame:Docta Complutenseinstname:Universidad Complutense de Madrid (UCM)InglésengInstituto de Salud Carlos III http://dx.doi.org/10.13039/501100004587 Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII) PI19%2F00886 ESTRES Y ALCOHOL COMO FACTORES DE RIESGO PSIQUIATRICO Y CARDIOVASCULAR ASOCIADOS A INFLAMACION: EVALUACION ANTIINFLAMATORIA DEL SISTEMA QUIMIOQUINA CX3CL1%2FCX3CR1Instituto de Salud Carlos III http://dx.doi.org/10.13039/501100004587 Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII) PI19%2F01577 ALCOHOL, DEPRESION Y DETERIORO COGNITIVO: PAPEL DE LAS ACILETANOLAMIDAS NO CANNABINOIDESInstituto de Salud Carlos III http://dx.doi.org/10.13039/501100004587 Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII) PI20%2F01399 PAPEL DE LA SEÑALIZACION LIPIDICA MEDIADA POR MONOACILGLICEROLES Y ACIDO LISOFOSFATIDICO EN LA ASOCIACION ENTRE TRASTORNOS POR USO DE ALCOHOL Y DEPRESION: IDENTIFICACION DE BIOMARCADORESInstituto de Salud Carlos III http://dx.doi.org/10.13039/501100004587 Plan Estatal de Investigación Científica, Técnica y de Innovación 2021-2023 PI22%2F00427 PAPEL DEL BDNF Y LAS ACILETANOLAMIDAS EN EL DETERIORO COGNITIVO ASOCIADO A LOS TRASTORNOS POR USO DE ALCOHOL: UN ESTUDIO TRASLACIONALopen accesshttp://purl.org/coar/access_right/c_abf2Attribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:docta.ucm.es:20.500.14352/1041522026-06-02T12:44:21Z
dc.title.none.fl_str_mv Antipsychotic medication influences the discriminative value of acylethanolamides as biomarkers of substance use disorder
title Antipsychotic medication influences the discriminative value of acylethanolamides as biomarkers of substance use disorder
spellingShingle Antipsychotic medication influences the discriminative value of acylethanolamides as biomarkers of substance use disorder
Herrera-Imbroda, Jesús
616.89
Substance use disorders
Biomarkers
Endocannabinoids
Acylethanolamides
Neuroleptics
Psychiatric co-morbidity
Psicofarmacología
Toxicología (Medicina)
32 Ciencias Médicas
title_short Antipsychotic medication influences the discriminative value of acylethanolamides as biomarkers of substance use disorder
title_full Antipsychotic medication influences the discriminative value of acylethanolamides as biomarkers of substance use disorder
title_fullStr Antipsychotic medication influences the discriminative value of acylethanolamides as biomarkers of substance use disorder
title_full_unstemmed Antipsychotic medication influences the discriminative value of acylethanolamides as biomarkers of substance use disorder
title_sort Antipsychotic medication influences the discriminative value of acylethanolamides as biomarkers of substance use disorder
dc.creator.none.fl_str_mv Herrera-Imbroda, Jesús
Flores-López, María
Requena-Ocaña, Nerea
Araos, Pedro
Ropero, Jessica
García Marchena, Nuria
Bordallo, Antonio
Suarez, Juan
Pavón-Morón, Francisco Javier
Serrano, Antonia
Mayoral, Fermín
Rodríguez De Fonseca, Fernando Antonio
author Herrera-Imbroda, Jesús
author_facet Herrera-Imbroda, Jesús
Flores-López, María
Requena-Ocaña, Nerea
Araos, Pedro
Ropero, Jessica
García Marchena, Nuria
Bordallo, Antonio
Suarez, Juan
Pavón-Morón, Francisco Javier
Serrano, Antonia
Mayoral, Fermín
Rodríguez De Fonseca, Fernando Antonio
author_role author
author2 Flores-López, María
Requena-Ocaña, Nerea
Araos, Pedro
Ropero, Jessica
García Marchena, Nuria
Bordallo, Antonio
Suarez, Juan
Pavón-Morón, Francisco Javier
Serrano, Antonia
Mayoral, Fermín
Rodríguez De Fonseca, Fernando Antonio
author2_role author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universidad Complutense de Madrid
dc.subject.none.fl_str_mv 616.89
Substance use disorders
Biomarkers
Endocannabinoids
Acylethanolamides
Neuroleptics
Psychiatric co-morbidity
Psicofarmacología
Toxicología (Medicina)
32 Ciencias Médicas
topic 616.89
Substance use disorders
Biomarkers
Endocannabinoids
Acylethanolamides
Neuroleptics
Psychiatric co-morbidity
Psicofarmacología
Toxicología (Medicina)
32 Ciencias Médicas
description Plasma acylethanolamides (NAEs), including the endocannabinoid anandamide (AEA), have been proposed as circulating biomarkers of substance use disorders. However, the concentration of these lipid transmitters might be influenced by the use of drugs prescribed for either the treatment of addiction or the associated psychiatric co-morbidities such as psychosis. As an example, neuroleptics, used for attenuation of psychotic symptoms and sedation, might theoretically interfere with the monoamine-mediated production of NAEs, obstructing the interpretation of plasma NAEsasclinical biomarkers. To solve the lack of information on the impact of neuroleptics on the concentration of NAEs, we evaluated the concentrations of NAEs in a control group and compared them to those present in (a) substance use disorders (SUD) patients that are not prescribed with neuroleptics, and (b) SUD patients (both alcohol use disorder and cocaine use disorder patients) using neuroleptics. The results demonstrate that SUD patients exhibited greater concentrations of NAEsthan the control population, affecting all species with the exception of stearoylethanolamide (SEA) and palmitoleoylethanolamide (POEA). Neuroleptic treatment enhanced the concentrations of NAEs, especially those of AEA, linoleoylethanolamide (LEA), and oleoylethanolamide (OEA). This effect of neuroleptic treatment was observed independently of the drug addiction that motivated the demand for treatment (either alcohol or cocaine). This study remarks the need to control the current use of psychotropic medication as a potential confounding variable when considering the use of NAEsasbiomarkers in SUD.
publishDate 2023
dc.date.none.fl_str_mv 2023
2023-05-27
2023
2023-05-27
dc.type.none.fl_str_mv journal article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/20.500.14352/104152
url https://hdl.handle.net/20.500.14352/104152
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.relation.none.fl_str_mv Instituto de Salud Carlos III http://dx.doi.org/10.13039/501100004587 Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII) PI19%2F00886 ESTRES Y ALCOHOL COMO FACTORES DE RIESGO PSIQUIATRICO Y CARDIOVASCULAR ASOCIADOS A INFLAMACION: EVALUACION ANTIINFLAMATORIA DEL SISTEMA QUIMIOQUINA CX3CL1%2FCX3CR1
Instituto de Salud Carlos III http://dx.doi.org/10.13039/501100004587 Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII) PI19%2F01577 ALCOHOL, DEPRESION Y DETERIORO COGNITIVO: PAPEL DE LAS ACILETANOLAMIDAS NO CANNABINOIDES
Instituto de Salud Carlos III http://dx.doi.org/10.13039/501100004587 Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII) PI20%2F01399 PAPEL DE LA SEÑALIZACION LIPIDICA MEDIADA POR MONOACILGLICEROLES Y ACIDO LISOFOSFATIDICO EN LA ASOCIACION ENTRE TRASTORNOS POR USO DE ALCOHOL Y DEPRESION: IDENTIFICACION DE BIOMARCADORES
Instituto de Salud Carlos III http://dx.doi.org/10.13039/501100004587 Plan Estatal de Investigación Científica, Técnica y de Innovación 2021-2023 PI22%2F00427 PAPEL DEL BDNF Y LAS ACILETANOLAMIDAS EN EL DETERIORO COGNITIVO ASOCIADO A LOS TRASTORNOS POR USO DE ALCOHOL: UN ESTUDIO TRASLACIONAL
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:Docta Complutense
instname:Universidad Complutense de Madrid (UCM)
instname_str Universidad Complutense de Madrid (UCM)
reponame_str Docta Complutense
collection Docta Complutense
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869404656967352320
score 15,301603

Similares en LA Referencia